Cambridge Biomagnetics

Location:London, UK
Speaker:Thanos Mitrelias
Primary Industry:Health & Medical Devices
Executive Summary:Cambridge Biomagnetics (CBM) will commercialise a generic technology for encoding chemical and biological compounds to perform ultra high throughput multiplexed assays with unprecedented speed and reliability. The assays are used in Clinical Diagnostics, Drug Discovery and Genome Sequencing; these are multi-billion dollar markets that show double digit annual growth rates. The company will also provide advanced multi-analyte biosensors to the health care industry by implementing our platform technology that is unique and offers the ability to customise products depending on the applications the end users require. It is a disruptive technology that can replace microarrays and is based on the development of magnetic microlabels that provide billions of unique codes to encode vast numbers of biochemical probes. In addition, the write ability of the technology will be utilised to synthesise and screen extremely large chemical libraries at a cost that is 1000 times less ($0.0001 per probe) than the cost of an assay performed with microarrays. CBM’s near term strategy is to develop a range of biosensors and collaborations with established companies to ensure a revenue stream while in parallel develop more sophisticated products.
Venture is:Seed Level


Corporate Presentations:

  • Air Products
  • BASF
  • Eastman Kodak Company
  • Genzyme
  • Goodrich
  • Hewlett-Packard
  • Honda
  • Medtronic
  • Merck
  • Sanyo

Reserved Presentations:

  • ExxonMobil
  • IBM

Partnering Events:
(full access included)

Platinum Sponsor

University of Hawaii

Press Sponsor

Business Wire

Commercialization Partner



Invest Australia AzTE Technology Enterprises

Media Sponsors

(joint with Nanotech 2007) Nature
Red Herring

Supporting Organizations

Boston University
Midwest Research University Network


“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
Matthew Laudon, Co-Founder and Director of TechConnect